Kombinationsbehandlung früher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa: Ergebnisse einer multizentrischen Studie

Autor:	Fischer Pa, Przuntek H, Welzel D, Majer M
Rok vydání:	2008
Předmět:	Levodopa medicine.medical_specialty Benserazide business.industry General Medicine Gastroenterology Treatment period Bromocriptine nervous system diseases Combined treatment Pharmacotherapy Multicenter study Internal medicine medicine PARKINSON'S SYNDROME business medicine.drug
Zdroj:	DMW - Deutsche Medizinische Wochenschrift. 109:1279-1283
ISSN:	1439-4413 0012-0472
DOI:	10.1055/s-2008-1069363
Popis:	125 patients in the early stages of Parkinson's syndrome were randomized and subjected to prearranged treatment adaptation period. Subsequently they were treated with either a mean dosage of 444 mg levodopa and benserazide (47 patients) or a combination of a mean of 298 mg levodopa and benserazide plus 17 mg bromocriptine (32 patients). Follow-up was done up to three years. Combined treatment permitted reduction of the levodopa dosage by 39%. As assessed by improvement of symptoms of Parkinson's syndrome in patients with a minimum treatment period of 1 or 3 years combined treatment was shown to be superior to monotherapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8c04a07f6a853dc0bf9678fd8a6edf64 https://doi.org/10.1055/s-2008-1069363 Zobrazit plný text záznamu